Clinical Trial Update: Safety and Efficacy Evaluation of IM19 Cells [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial examining the safety and early efficacy of IM19 Cells in patients with hematologic malignancies, sponsored by Beijing Immunochina Medic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• IM19 Cells

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Hematological Malignancies | Phase 1 | Status: UNKNOWN